SCHEMBL2018141

SCHEMBL2018141

CN(C)c1ccc(-c2nnc(-c3cn4c5c(cccc35)CCC4)o2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.46
RAB9A P51151 4/20 0.46
RXFP1 Q9HBX9 2/20 0.46
APP P05067 1/20 0.43
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
MAPT P10636 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.41
HCRTR1 O43613 1/20 0.41
NFKB1 P19838 1/20 0.41
CASP3 P42574 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
HTR2A P28223 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020405 0.88 NPC1 (0.43) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2021453 0.86 RAB9A (0.49) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2020602 0.85 NPC1 (0.44) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2015858 0.85 RAB9A (0.48) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2019352 0.85 NPC1 (0.46) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2016725 0.85 S1PR1 (0.46) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2019393 0.85 HTR2A (0.43) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2019229 0.83 KDM4E (0.47) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2015370 0.81 NPC1 (0.48) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL2021179 0.81 RAB9A (0.51) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 NPC1 235/4885RAB9A 1649/4885RXFP1 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.